Prosecution Insights
Prosecution Insights
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (20%) |
| No statute on record | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCDOWELL, BRIAN E | 1 | 74.3% | +30.6% |
| COLEMAN, BRENDA LIBBY | 1 | 74.7% | +15.7% |
| SANCHEZ, JUSTIN CHRISTOPHER | 1 | 86.5% | +11.5% |
| TCHERKASSKAYA, OLGA V | 1 | 55.4% | +46.6% |
| ANDERSON, REBECCA L | 1 | 73.2% | +24.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18023164 | NOVEL COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | COLEMAN, BRENDA LIBBY | 11d overdue |
| 17920558 | NEW CAPSULE COMPOSITION FOR PERORAL ADMINISTRATION | TCHERKASSKAYA, OLGA V | 9d |
| 18283489 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | SANCHEZ, JUSTIN CHRISTOPHER | 16d |
| 18577856 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | MCDOWELL, BRIAN E | 30d |
| 17912284 | NOVEL COMPOUNDS USEFUL IN THE TREATMENT AND/OR PREVENTION OF A DISEASE, DISORDER OR CONDITION ASSOCIATED WITH ANGIOTENSIN II | ANDERSON, REBECCA L | 63d |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1622 | 1 |
| 1615 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18577856 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | MCDOWELL, BRIAN E | 1624 | — | Non-Final OA | 30d | Pending | Jan 09, 2024 |
| 18023164 | NOVEL COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | COLEMAN, BRENDA LIBBY | 1624 | Other | Non-Final OA | 11d overdue | Pending | Oct 10, 2023 |
| 18283489 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | Other | Non-Final OA | 16d | Pending | Sep 22, 2023 |
| 17920558 | NEW CAPSULE COMPOSITION FOR PERORAL ADMINISTRATION | TCHERKASSKAYA, OLGA V | 1615 | Other | Final Rejection | 9d | Pending | Oct 21, 2022 |
| 17912284 | NOVEL COMPOUNDS USEFUL IN THE TREATMENT AND/OR PREVENTION OF A DISEASE, DISORDER OR CONDITION ASSOCIATED WITH ANGIOTENSIN II | ANDERSON, REBECCA L | 1626 | §112 | Final Rejection | 63d | Pending | Sep 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial